Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.59 |
| ▸ | PLA2G2A | P14555 | 8/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HRH2 | P25021 | 2/20 | 0.52 |
| ▸ | HRH1 | P35367 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16256950 | 0.85 | KCNA5 (0.60) | DRD2PLA2G2ATHRBALDH1A1HRH2 | |
| SCHEMBL1177610 | 0.85 | LSS (0.65) | DRD2PLA2G2ATHRBSIGMAR1HRH2 | |
| SCHEMBL19562228 | 0.84 | DRD2 (0.54) | DRD2PLA2G2ATHRBSIGMAR1ALDH1A1 | |
| SCHEMBL11939472 | 0.84 | POLB (0.56) | DRD2POLB | |
| SCHEMBL11938971 | 0.84 | DRD2 (0.54) | DRD2PLA2G2ATHRBSIGMAR1ALDH1A1 | |
| SCHEMBL6248913 | 0.84 | HRH3 (0.74) | DRD2ALDH1A1 | |
| SCHEMBL10722663 | 0.84 | DRD2 (0.69) | DRD2SIGMAR1ALDH1A1HRH2HRH1 | |
| SCHEMBL4376369 | 0.83 | DRD2 (0.66) | DRD2PLA2G2ATHRBSIGMAR1ALDH1A1 | |
| SCHEMBL6488394 | 0.82 | PLA2G2A (0.60) | DRD2PLA2G2ATHRBSIGMAR1HRH2 | |
| SCHEMBL1177617 | 0.82 | HRH3 (0.75) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101511807-A | Substituted benzamide modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-19 | — | — | CN | claimed |
| EP-2038269-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-25 | — | — | EP | claimed |
| US-20080045507-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | claimed |
| WO-2008002816-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | WO | claimed |
| CN-101511807-A | Substituted benzamide modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-19 | — | — | CN | disclosed |
| EP-2038269-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-25 | — | — | EP | disclosed |
| US-20080045507-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045507-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045507-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| WO-2008002816-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008002816-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045507-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH2 | DRD2 1486/4885PLA2G2A 1710/4885THRB 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.